MEDICATION-ASSISTED TREATMENT CENTERS OF EXCELLENCE

Feb 3, 2023 **BIWEEKLY NEWSLETTER** Vol. 67



TRENDS AND CHARACTERISTICS OF BUPRENORPHINE-INVOLVED OVERDOSE DEATHS PRIOR TO AND DURING THE COVID-19 PANDEMIC

This was a cross-sectional study of over 74k opioid-involved overdose deaths to determine whether buprenorphine-involved overdose deaths were different after the implementation of flexibilities for buprenorphine prescription during COVID-19. It found that buprenorphine was involved in <3% for both all drug overdose deaths and opioid-involved overdose deaths during July 2019 to June 2021, during which overdose deaths actually skyrocketed. This suggests that buprenorphine treatment for OUD during the pandemic was not associated with an increased proportion of overdose deaths and emphasized continued access concerns during the pandemic, especially since many of those patients were not taking buprenorphine.

WHAT'S INSIDE

UPCOMING EVENTS

2/10: ECHO: Implications of the X-Waiver Removal in NJ

2/15: New Approaches to the Neuroscience of Drug Addiction

2/16: OBAT Navigator Skills Lab

3/2: Myths and Realities of Harm Reduction

HEADLINES

Community, Network, & Individual Level Predictors of Uptake of MOUD Among Young People

A Novel Inpatient Buprenorphine Induction Program for Adolescents With OUD

Removal of DATA Waiver (X-Waiver) Requirement

RESOURCES

SNJ COE Expands Statewide Services

UPCOMING EVENTS



SUD MAT PROJECT ECHO: IMPLICATIONS OF THE X-WAIVER REMOVAL IN NJ

FRIDAY, FEBRUARY 10TH FROM 12:00-1:00 PM

Project ECHO is straight-forward, specific and applicable. At every live session we explore active patient challenges from multiple perspectives. We each hold a piece of the puzzle and everyone is welcome to share experiences. You'll meet practitioners from across the state through a simple video interface and become part of a collegial community. You'll have a comfortable place to return and will build on what you're learning, month to month.

NEW APPROACHES TO THE NEUROSCIENCE OF HUMAN DRUG ADDICTION: DRUG BIAS, NATURAL LANGUAGE PROCESSING AND THE SYNCHRONIZED BRAIN

WEDNESDAY, FEBRUARY 15TH FROM 11:00 AM-12:00 PM

The Rutgers University Center for Molecular and Behavioral Neuroscience Colloquium Series will feature Guest Speaker Rita Goldstein, Ph.D., Professor of Neuroimaging & Addiction at the Dept of Psychiatry of Icahn School of Medicine Mount Sinai, will discuss two studies in which context is generated along with the stimulus representation through feed-forward computations. Together these two studies reveal synaptic and circuit mechanisms underlying key visual computations.

OBAT MONTHLY SUD NAVIGATION SUPPORT CALLS

THURSDAY, FEBRUARY 16TH FROM 12:00-1:00 PM

The Camden Coalition offers monthly resources calls & skills labs (every 3rd Thursday) to provide ongoing opportunity for OBAT navigators & other SUD navigators/case managers to continue learning through:

- Hour-long deep dive of particular content areas
- Discussion of (de-identified) patient cases & support thinking through patient engagement strategies, potential resources, & how to practice self-care while doing this work
- Presentations & sharing updated resources about relevant topics

MYTHS AND REALITIES OF HARM REDUCTION: A PANEL DISCUSSION

FRIDAY, MARCH 2ND FROM 1:00-3:00 PM

LOCATION: MONTCLAIR STATE UNIVERSITY BUSINESS SCHOOL, 1ST FLOOR, ROOM 101

NJ lost nearly 3,000 people to preventable drug overdoses in 2022. Harm reduction, a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use, can help save lives. Join the panel of experts, including our Clinical Pharmacist/Academic Detailer, Dr. Clement Chen to learn about harm reduction strategies and their potential for helping people who use drugs stay alive.

RECENT NEWS

COMMUNITY-, NETWORK-, AND INDIVIDUAL-LEVEL PREDICTORS OF UPTAKE OF MEDICATION FOR OPIOID USE DISORDER AMONG YOUNG PEOPLE WHO INJECT DRUGS AND THEIR NETWORKS: A MULTILEVEL ANALYSIS

This longitudinal study aimed to explore a holistic and multilevel understanding of individual-level, network-level, and community-level characteristics and how they affected MOUD uptake among young people who inject drugs and their support network. It found that stigma was significantly associated with MOUD uptake in both individual and community levels. However, more individual-level stigma was associated with a higher likelihood of MOUD uptake, whereas having a more community-level "normative" stigma was associated with a lower likelihood of MOUD uptake. Polysubstance use and having a larger support network were associated with a greater likelihood of MOUD uptake. As the study states, more research is warranted to examine these predictors so that they can inform interventions to address these barriers to MOUD.

A NOVEL INPATIENT BUPRENORPHINE INDUCTION PROGRAM FOR ADOLESCENTS WITH OPIOID USE DISORDER

Adolescent morbidity and mortality due to opioid use disorder have risen. This study examined the opportunity to induct buprenorphine in an inpatient pediatric setting to address barriers to MOUD access for adolescents. During May 2021 to July 2022, 46 admissions for 36 patients were completed for those between 12 to 21 years of age. All used fentanyl and no other opioids. 87% of admissions resulted in a successful buprenorphine induction, and 3 additional patients never developed withdrawal symptoms and were discharged with maintenance buprenorphine. Linkage to ongoing treatment occurred within 2 weeks for 72% of admissions for which buprenorphine was started. These results provide promising preliminary evidence of the feasibility of inpatient buprenorphine induction for adolescents with OUD, and the use of buprenorphine in adolescents. Given the public health urgency and lack of adolescent access to MOUD, these results should guide further research in the expansion of access to evidence-based buprenorphine to younger patients.

REMOVAL OF DATA WAIVER (X-WAIVER) REQUIREMENT - FROM SAMHSA WEBSITE

Section 1262 of the Consolidated Appropriations Act, 2023, removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe MOUD. With this provision, and effective immediately, SAMHSA will no longer be accepting NOIs (waiver applications). All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for OUD in their practice if permitted by applicable state law and SAMHSA encourages them to do so. SAMHSA and DEA are actively working on implementation of a separate provision of the Omnibus related to training requirements for DEA registration that becomes effective in June 2023. Please continue to check this webpage for further updates and guidance.

Providers should continually check this page for updates to guidance on the removal of the X-waiver.

RESOURCES



SOUTHERN NJ MATCOE EXPANDS STATEWIDE TRAINING, EDUCATION, & CONSULT SERVICES

As part of our mission to increase statewide capacity to provide standard of care treatment for patients with SUD through mentoring and education, $500,000 in expansion funding has been awarded to our partners at Cooper University Health Care and Rowan-Virtua School of Osteopathic Medicine. This funding will allow the Southern NJ team to expand medical education trainings on a large-scale, offering both didactic and asynchronous forms of educational content in varied lengths with provision of free CME for physicians and CME designations for advanced practice providers. The team is also expanding "elbow to elbow" consultation services both on-site and through "office hours" in virtual capacity for physicians, APPs, and interdisciplinary clinical staff in order to further address clinical practice-based and logistical issues.

The first training, in didactic "live" webinar format, is scheduled for Friday, February 17 from 7:30am to 9:30am. We will focus on buprenorphine initiation in the ED and OBAT settings, which will be presented by Cooper University Health Care Center for Healing Medical Director and SNJ MATCOE PI, Rachel Haroz, MD, FAACT; Rowan-Virtua School of Osteopathic Medicine Vice Dean and SNJ MATCOE PI/Director, Richard Jermyn, DO, FAAPMR; and Cooper University Health Care Center for Healing Addiction Medicine Specialist, Rachel Ehrman-Dupre, MD. Please view and share the **flyer for the first training,** in addition to the **training content preview.**

For registration and CME information and further information in regards to the training series/related trainings, contact SNJ MATCOE Content Manager, Patricia Fortunato: fortunato-patricia@cooperhealth.edu

MEDICATION-ASSISTED TREATMENT
CENTERS OF EXCELLENCE

24/7 MAT Provider Hotline: 844-HELP OUD (844-435-7683)

Northern NJ MAT COE Website & Email
Southern NJ MAT COE Website & Email